Effects of topical Polymyxin Neomycin Hydrocortison in Patients with Non-Allergic Rhinitis, a randomized clinical trial.
Background and aims: Bacterial infection is involved in the pathogenesis of inflammatory non-allergic rhinitis (NAR), and a broad-spectrum antibiotic should reduce the severity of the disease by eliminating the mucosal biofilm. The purpose of this study is to assess the efficacy of a topical mixtur...
        Saved in:
      
    
          | Main Authors: | Majid Mirsadraee, Sara Mollazadeh, Negin Ghiyasimoghaddam | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Tehran University of Medical Sciences
    
        2024-11-01 | 
| Series: | Journal of Medical Bacteriology | 
| Subjects: | |
| Online Access: | https://jmb.tums.ac.ir/index.php/jmb/article/view/532 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Formulation of Neomycin Sulphate 0.35 %(w/v) & Hydrocortisone 0.5% Otic Drop        
                          
 by: Muhammad Jassim Muhammad, et al.
 Published: (2022-06-01)
- 
                
                    Assessment and management of allergic rhinitis: A review and evidence‐informed approach for family medicine        
                          
 by: Akash Jangan, et al.
 Published: (2024-11-01)
- 
                
                    Pharmacoeconomic evaluation of the modern nasal corticosteroids for the allergic rhinitis treatment.        
                          
 by: A. G. Zadorozhna, et al.
 Published: (2018-04-01)
- 
                
                    Correlations of Nasal Microbiome with Allergic Rhinitis and Its Symptoms Severity in Children Progression        
                          
 by: Teng Z, et al.
 Published: (2024-11-01)
- 
                
                    The Association of Nasal and Blood Eosinophils with Serum IgE Level in Allergic Rhinitis and Asthma: A Case‐Control Study        
                          
 by: Mehdi Torabizadeh, et al.
 Published: (2024-11-01)
 
       